UA62913C2 - ItarasPHARMACEUTICAL COMPOSITION BASED ON a1L-AGONSISTS FOR TREATING INCONTINENCE (VARIANTS) AND PHENYLAMINOIMIDASOLIN (VARIANTS) - Google Patents

ItarasPHARMACEUTICAL COMPOSITION BASED ON a1L-AGONSISTS FOR TREATING INCONTINENCE (VARIANTS) AND PHENYLAMINOIMIDASOLIN (VARIANTS) Download PDF

Info

Publication number: UA62913C2
Authority: UA; Ukraine
Prior art keywords: carbon atoms; hydrogen; methyl; alkyl containing; trifluoromethyl
Prior art date: 1995-04-20

Application number

UA97115588A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Berinher Inhelheim Kg

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-04-20

Filing date

1996-04-13

Publication date

2004-01-15

1996-04-13 Application filed by Berinher Inhelheim Kg filed Critical Berinher Inhelheim Kg

2004-01-15 Publication of UA62913C2 publication Critical patent/UA62913C2/uk

Links

206010021639 Incontinence Diseases 0.000 title abstract 2
239000000203 mixture Substances 0.000 title description 3
239000000556 agonist Substances 0.000 claims abstract description 8
125000004432 carbon atom Chemical group C* 0.000 claims description 127
239000001257 hydrogen Substances 0.000 claims description 79
229910052739 hydrogen Inorganic materials 0.000 claims description 79
125000000217 alkyl group Chemical group 0.000 claims description 65
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 60
150000002431 hydrogen Chemical class 0.000 claims description 32
WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 30
GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 30
229910052794 bromium Inorganic materials 0.000 claims description 30
239000000460 chlorine Substances 0.000 claims description 30
125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 30
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 29
229910052801 chlorine Inorganic materials 0.000 claims description 29
150000001875 compounds Chemical class 0.000 claims description 28
150000004820 halides Chemical class 0.000 claims description 27
125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 24
125000004433 nitrogen atom Chemical group N* 0.000 claims description 22
125000003545 alkoxy group Chemical group 0.000 claims description 21
125000000753 cycloalkyl group Chemical group 0.000 claims description 17
-1 B2 - methyl Substances 0.000 claims description 16
125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 15
125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 15
125000005544 phthalimido group Chemical group 0.000 claims description 15
125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims description 15
PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 13
239000011737 fluorine Substances 0.000 claims description 13
229910052731 fluorine Inorganic materials 0.000 claims description 13
150000003839 salts Chemical class 0.000 claims description 13
239000002253 acid Substances 0.000 claims description 12
125000002252 acyl group Chemical group 0.000 claims description 11
239000008194 pharmaceutical composition Substances 0.000 claims description 11
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
239000013543 active substance Substances 0.000 claims description 10
229910052757 nitrogen Inorganic materials 0.000 claims description 10
125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 9
YJWCIKMTOSENCW-UHFFFAOYSA-N 1-n-(4,5-dihydro-1h-imidazol-2-yl)-3-n,3-n,2-trimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=CC(N=C2NCCN2)=C1C YJWCIKMTOSENCW-UHFFFAOYSA-N 0.000 claims description 8
206010066218 Stress Urinary Incontinence Diseases 0.000 claims description 8
125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 8
208000022170 stress incontinence Diseases 0.000 claims description 8
125000001424 substituent group Chemical group 0.000 claims description 8
YATKIBKWDXFJQD-UHFFFAOYSA-N 4-bromo-3-n-(4,5-dihydro-1h-imidazol-2-yl)-1-n,1-n,2-trimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=C(Br)C(N=C2NCCN2)=C1C YATKIBKWDXFJQD-UHFFFAOYSA-N 0.000 claims description 7
JCOPITWIWLFFPC-UHFFFAOYSA-N n-phenyl-4,5-dihydro-1h-imidazol-2-amine Chemical class N1CCN=C1NC1=CC=CC=C1 JCOPITWIWLFFPC-UHFFFAOYSA-N 0.000 claims description 7
125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 7
206010046543 Urinary incontinence Diseases 0.000 claims description 6
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 5
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 5
125000005842 heteroatom Chemical group 0.000 claims description 5
239000001301 oxygen Substances 0.000 claims description 5
229910052760 oxygen Inorganic materials 0.000 claims description 5
239000000546 pharmaceutical excipient Substances 0.000 claims description 5
239000000126 substance Substances 0.000 claims description 5
239000011593 sulfur Substances 0.000 claims description 5
229910052717 sulfur Inorganic materials 0.000 claims description 5
229920006395 saturated elastomer Polymers 0.000 claims description 4
OXJQUPLGCMQUPR-UHFFFAOYSA-N 2-[3-(4,5-dihydro-1h-imidazol-2-ylamino)-2-methylphenyl]isoindole-1,3-dione Chemical compound C1=CC=C(N2C(C3=CC=CC=C3C2=O)=O)C(C)=C1N=C1NCCN1 OXJQUPLGCMQUPR-UHFFFAOYSA-N 0.000 claims description 3
ZJYLXNKNNWYWJI-UHFFFAOYSA-N 2-[4-chloro-3-(4,5-dihydro-1h-imidazol-2-ylamino)phenyl]isoindole-1,3-dione Chemical compound ClC1=CC=C(N2C(C3=CC=CC=C3C2=O)=O)C=C1N=C1NCCN1 ZJYLXNKNNWYWJI-UHFFFAOYSA-N 0.000 claims description 3
TUJQUSVKLISURX-UHFFFAOYSA-N 3-n-(4,5-dihydro-1h-imidazol-2-yl)-2-methylbenzene-1,3-diamine Chemical compound CC1=C(N)C=CC=C1N=C1NCCN1 TUJQUSVKLISURX-UHFFFAOYSA-N 0.000 claims description 3
HIXKLJMPISBCTB-UHFFFAOYSA-N 4-bromo-1-n-(4,5-dihydro-1h-imidazol-2-yl)-3-n,3-n,2-trimethylbenzene-1,3-diamine Chemical compound CN(C)C1=C(Br)C=CC(N=C2NCCN2)=C1C HIXKLJMPISBCTB-UHFFFAOYSA-N 0.000 claims description 3
ZBTNRNNXVHIZSX-UHFFFAOYSA-N 4-chloro-3-n-(4,5-dihydro-1h-imidazol-2-yl)-6-methylbenzene-1,3-diamine Chemical compound C1=C(N)C(C)=CC(Cl)=C1N=C1NCCN1 ZBTNRNNXVHIZSX-UHFFFAOYSA-N 0.000 claims description 3
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
AEMOLEFTQBMNLQ-SYJWYVCOSA-N (2s,3s,4s,5s,6r)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid Chemical compound O[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H]1O AEMOLEFTQBMNLQ-SYJWYVCOSA-N 0.000 claims description 2
NHJIANDCSNCVHP-UHFFFAOYSA-N 4-chloro-3-n-(4,5-dihydro-1h-imidazol-2-yl)-1-n,1-n,2-trimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=C(Cl)C(N=C2NCCN2)=C1C NHJIANDCSNCVHP-UHFFFAOYSA-N 0.000 claims description 2
125000003277 amino group Chemical group 0.000 claims description 2
125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 claims description 2
UCFFGYASXIPWPD-UHFFFAOYSA-N methyl hypochlorite Chemical compound COCl UCFFGYASXIPWPD-UHFFFAOYSA-N 0.000 claims description 2
DESQSCXTLOLOOG-UHFFFAOYSA-N n-[2-chloro-5-(trifluoromethyl)phenyl]-4,5-dihydro-1h-imidazol-2-amine;nitric acid Chemical compound O[N+]([O-])=O.FC(F)(F)C1=CC=C(Cl)C(NC=2NCCN=2)=C1 DESQSCXTLOLOOG-UHFFFAOYSA-N 0.000 claims description 2
125000001624 naphthyl group Chemical group 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
FZSDBXOMBKVTLD-UHFFFAOYSA-N 4,6-dibromo-1-n-(4,5-dihydro-1h-imidazol-2-yl)-3-n,3-n,2-trimethylbenzene-1,3-diamine Chemical compound CN(C)C1=C(Br)C=C(Br)C(N=C2NCCN2)=C1C FZSDBXOMBKVTLD-UHFFFAOYSA-N 0.000 claims 2
239000000945 filler Substances 0.000 claims 2
YUBQLTCZHAZBJF-UHFFFAOYSA-N 2,4-dichloro-3-N-(4,5-dihydro-1H-imidazol-2-yl)-1-N,1-N-dimethylbenzene-1,3-diamine Chemical compound CN(C=1C(=C(C(=CC=1)Cl)N=C1NCCN1)Cl)C YUBQLTCZHAZBJF-UHFFFAOYSA-N 0.000 claims 1
JGXAEMVGSPDMLD-UHFFFAOYSA-N N-phenylimidazolidin-1-amine Chemical class N1(CNCC1)NC1=CC=CC=C1 JGXAEMVGSPDMLD-UHFFFAOYSA-N 0.000 claims 1
230000002378 acidificating effect Effects 0.000 claims 1
239000000654 additive Substances 0.000 claims 1
230000000996 additive effect Effects 0.000 claims 1
RZYXZFQITKJLGF-UHFFFAOYSA-N n-phenyl-4h-imidazol-5-amine Chemical class C1NC=NC1=NC1=CC=CC=C1 RZYXZFQITKJLGF-UHFFFAOYSA-N 0.000 claims 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 9
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical group C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 9
239000000243 solution Substances 0.000 description 8
230000036772 blood pressure Effects 0.000 description 7
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
230000009471 action Effects 0.000 description 6
229940088623 biologically active substance Drugs 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
238000000034 method Methods 0.000 description 6
229960001802 phenylephrine Drugs 0.000 description 6
238000010992 reflux Methods 0.000 description 6
210000003708 urethra Anatomy 0.000 description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
238000009835 boiling Methods 0.000 description 5
238000002360 preparation method Methods 0.000 description 5
239000000047 product Substances 0.000 description 5
238000003786 synthesis reaction Methods 0.000 description 5
CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 4
KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical group C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
239000008298 dragée Substances 0.000 description 4
235000019441 ethanol Nutrition 0.000 description 4
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
SONNWYBIRXJNDC-VIFPVBQESA-N phenylephrine Chemical compound CNC[C@H](O)C1=CC=CC(O)=C1 SONNWYBIRXJNDC-VIFPVBQESA-N 0.000 description 4
SSOLNOMRVKKSON-UHFFFAOYSA-N proguanil Chemical compound CC(C)\N=C(/N)N=C(N)NC1=CC=C(Cl)C=C1 SSOLNOMRVKKSON-UHFFFAOYSA-N 0.000 description 4
235000000346 sugar Nutrition 0.000 description 4
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
229920002472 Starch Polymers 0.000 description 3
YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
239000008346 aqueous phase Substances 0.000 description 3
229910052799 carbon Inorganic materials 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
230000002035 prolonged effect Effects 0.000 description 3
239000008107 starch Substances 0.000 description 3
235000019698 starch Nutrition 0.000 description 3
239000000454 talc Substances 0.000 description 3
229910052623 talc Inorganic materials 0.000 description 3
235000012222 talc Nutrition 0.000 description 3
HFCFJYRLBAANKN-UHFFFAOYSA-N 2-methyl-3-nitroaniline Chemical compound CC1=C(N)C=CC=C1[N+]([O-])=O HFCFJYRLBAANKN-UHFFFAOYSA-N 0.000 description 2
QYPPUFQYPQBDPR-UHFFFAOYSA-N 3-n,3-n,2-trimethylbenzene-1,3-diamine Chemical compound CN(C)C1=CC=CC(N)=C1C QYPPUFQYPQBDPR-UHFFFAOYSA-N 0.000 description 2
244000215068 Acacia senegal Species 0.000 description 2
108060003345 Adrenergic Receptor Proteins 0.000 description 2
102000017910 Adrenergic receptor Human genes 0.000 description 2
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
229920002261 Corn starch Polymers 0.000 description 2
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 2
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
229920000084 Gum arabic Polymers 0.000 description 2
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
241000283973 Oryctolagus cuniculus Species 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
239000000205 acacia gum Substances 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
150000007513 acids Chemical class 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
239000001506 calcium phosphate Substances 0.000 description 2
229910000389 calcium phosphate Inorganic materials 0.000 description 2
235000011010 calcium phosphates Nutrition 0.000 description 2
239000002775 capsule Substances 0.000 description 2
239000001768 carboxy methyl cellulose Substances 0.000 description 2
239000000969 carrier Substances 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
238000000576 coating method Methods 0.000 description 2
238000001816 cooling Methods 0.000 description 2
239000008120 corn starch Substances 0.000 description 2
VAYGXNSJCAHWJZ-UHFFFAOYSA-N dimethyl sulfate Chemical compound COS(=O)(=O)OC VAYGXNSJCAHWJZ-UHFFFAOYSA-N 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
239000003480 eluent Substances 0.000 description 2
239000012259 ether extract Substances 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
239000000284 extract Substances 0.000 description 2
239000011521 glass Substances 0.000 description 2
125000000623 heterocyclic group Chemical group 0.000 description 2
150000003840 hydrochlorides Chemical class 0.000 description 2
XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 2
IQXFQTQAXAPESE-UHFFFAOYSA-N imidazolidine;hydrobromide Chemical compound Br.C1CNCN1 IQXFQTQAXAPESE-UHFFFAOYSA-N 0.000 description 2
MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
150000002462 imidazolines Chemical class 0.000 description 2
238000002347 injection Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
235000019359 magnesium stearate Nutrition 0.000 description 2
229910052943 magnesium sulfate Inorganic materials 0.000 description 2
235000019341 magnesium sulphate Nutrition 0.000 description 2
229940126601 medicinal product Drugs 0.000 description 2
BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
238000002156 mixing Methods 0.000 description 2
210000003903 pelvic floor Anatomy 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000011541 reaction mixture Substances 0.000 description 2
239000000741 silica gel Substances 0.000 description 2
229910002027 silica gel Inorganic materials 0.000 description 2
235000011121 sodium hydroxide Nutrition 0.000 description 2
239000000829 suppository Substances 0.000 description 2
239000006188 syrup Substances 0.000 description 2
235000020357 syrup Nutrition 0.000 description 2
VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 2
UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 2
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
125000001376 1,2,4-triazolyl group Chemical group N1N=C(N=C1)* 0.000 description 1
RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
HKWFCVUHNYCCNR-UHFFFAOYSA-N 1-n-(4,5-dihydro-1h-imidazol-2-yl)-4-fluorobenzene-1,3-diamine Chemical compound C1=C(F)C(N)=CC(N=C2NCCN2)=C1 HKWFCVUHNYCCNR-UHFFFAOYSA-N 0.000 description 1
QMVOITDAPWOGIU-UHFFFAOYSA-N 1-n-(4,5-dihydro-1h-imidazol-2-yl)-4-methylbenzene-1,3-diamine Chemical compound C1=C(N)C(C)=CC=C1N=C1NCCN1 QMVOITDAPWOGIU-UHFFFAOYSA-N 0.000 description 1
JOMNTHCQHJPVAZ-UHFFFAOYSA-N 2-methylpiperazine Chemical compound CC1CNCCN1 JOMNTHCQHJPVAZ-UHFFFAOYSA-N 0.000 description 1
MSYFITFSZJKRQJ-UHFFFAOYSA-N 4,5-dihydroimidazol-1-amine Chemical class NN1CCN=C1 MSYFITFSZJKRQJ-UHFFFAOYSA-N 0.000 description 1
GZVOUIIHCGLYNB-UHFFFAOYSA-N 4,6-dibromo-3-n-(4,5-dihydro-1h-imidazol-2-yl)-2-methylbenzene-1,3-diamine Chemical compound CC1=C(N)C(Br)=CC(Br)=C1N=C1NCCN1 GZVOUIIHCGLYNB-UHFFFAOYSA-N 0.000 description 1
OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-M 4-hydroxybenzoate Chemical compound OC1=CC=C(C([O-])=O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-M 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N 4-hydroxybenzoic acid Chemical class OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
HCXJFMDOHDNDCC-UHFFFAOYSA-N 5-$l^{1}-oxidanyl-3,4-dihydropyrrol-2-one Chemical group O=C1CCC(=O)[N]1 HCXJFMDOHDNDCC-UHFFFAOYSA-N 0.000 description 1
NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical group OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
DNCKMGPDTBVHAK-UHFFFAOYSA-N CC1=CC=C(F)C=C1N=C1NCCN1.CC1=C(Br)C=CC=C1N=C1NCCN1.ClC1=CC(Cl)=CC=C1N=C1NCCN1.FC(F)(F)C1=CC=C(Cl)C(N=C2NCCN2)=C1 Chemical compound CC1=CC=C(F)C=C1N=C1NCCN1.CC1=C(Br)C=CC=C1N=C1NCCN1.ClC1=CC(Cl)=CC=C1N=C1NCCN1.FC(F)(F)C1=CC=C(Cl)C(N=C2NCCN2)=C1 DNCKMGPDTBVHAK-UHFFFAOYSA-N 0.000 description 1
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
244000223760 Cinnamomum zeylanicum Species 0.000 description 1
235000005979 Citrus limon Nutrition 0.000 description 1
244000131522 Citrus pyriformis Species 0.000 description 1
NUTAGZUETIAHHI-UHFFFAOYSA-N ClC1=CC(C)=CC=C1N=C1NCCN1.CC1=CC=CC(Cl)=C1N=C1NCCN1.ClC1=CC=CC(Cl)=C1N=C1NCCN1.CCC1=CC=CC(CC)=C1N=C1NCCN1 Chemical compound ClC1=CC(C)=CC=C1N=C1NCCN1.CC1=CC=CC(Cl)=C1N=C1NCCN1.ClC1=CC=CC(Cl)=C1N=C1NCCN1.CCC1=CC=CC(CC)=C1N=C1NCCN1 NUTAGZUETIAHHI-UHFFFAOYSA-N 0.000 description 1
206010011224 Cough Diseases 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical class OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
102100039555 Galectin-7 Human genes 0.000 description 1
101000887163 Gallus gallus Gallinacin-4 Proteins 0.000 description 1
101000887166 Gallus gallus Gallinacin-7 Proteins 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
239000007868 Raney catalyst Substances 0.000 description 1
NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 1
229910000564 Raney nickel Inorganic materials 0.000 description 1
YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 1
229920001800 Shellac Polymers 0.000 description 1
FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 1
XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
244000126014 Valeriana officinalis Species 0.000 description 1
235000013832 Valeriana officinalis Nutrition 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
102000015007 alpha-adrenergic receptor activity proteins Human genes 0.000 description 1
108040006816 alpha-adrenergic receptor activity proteins Proteins 0.000 description 1
229910021529 ammonia Inorganic materials 0.000 description 1
239000003708 ampul Substances 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
206010003549 asthenia Diseases 0.000 description 1
125000004429 atom Chemical group 0.000 description 1
230000008901 benefit Effects 0.000 description 1
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
230000031709 bromination Effects 0.000 description 1
238000005893 bromination reaction Methods 0.000 description 1
229910000019 calcium carbonate Inorganic materials 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940096529 carboxypolymethylene Drugs 0.000 description 1
210000000748 cardiovascular system Anatomy 0.000 description 1
239000003054 catalyst Substances 0.000 description 1
239000003518 caustics Substances 0.000 description 1
239000001913 cellulose Substances 0.000 description 1
229920002678 cellulose Polymers 0.000 description 1
230000035606 childbirth Effects 0.000 description 1
235000017803 cinnamon Nutrition 0.000 description 1
229940125782 compound 2 Drugs 0.000 description 1
229940125898 compound 5 Drugs 0.000 description 1
239000007859 condensation product Substances 0.000 description 1
230000008602 contraction Effects 0.000 description 1
229940109275 cyclamate Drugs 0.000 description 1
125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
125000004186 cyclopropylmethyl group Chemical group [H]C([H])(*)C1([H])C([H])([H])C1([H])[H] 0.000 description 1
230000006378 damage Effects 0.000 description 1
IEJIGPNLZYLLBP-UHFFFAOYSA-N dimethyl carbonate Chemical compound COC(=O)OC IEJIGPNLZYLLBP-UHFFFAOYSA-N 0.000 description 1
POLCUAVZOMRGSN-UHFFFAOYSA-N dipropyl ether Chemical compound CCCOCCC POLCUAVZOMRGSN-UHFFFAOYSA-N 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000007884 disintegrant Substances 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
230000000694 effects Effects 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
239000003925 fat Substances 0.000 description 1
150000002191 fatty alcohols Chemical class 0.000 description 1
210000003608 fece Anatomy 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
235000019253 formic acid Nutrition 0.000 description 1
125000002541 furyl group Chemical group 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
235000011187 glycerol Nutrition 0.000 description 1
239000008187 granular material Substances 0.000 description 1
125000005843 halogen group Chemical group 0.000 description 1
125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
229910000043 hydrogen iodide Inorganic materials 0.000 description 1
125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
150000002461 imidazolidines Chemical class 0.000 description 1
125000002636 imidazolinyl group Chemical group 0.000 description 1
125000002883 imidazolyl group Chemical group 0.000 description 1
239000003701 inert diluent Substances 0.000 description 1
230000030214 innervation Effects 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000007915 intraurethral administration Methods 0.000 description 1
INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 1
125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
125000001786 isothiazolyl group Chemical group 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000009245 menopause Effects 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
230000027939 micturition Effects 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
239000011707 mineral Substances 0.000 description 1
230000004899 motility Effects 0.000 description 1
BFGSSXYIVHXPCN-UHFFFAOYSA-N n-(2-chloro-3-methylphenyl)-4,5-dihydro-1h-imidazol-2-amine Chemical compound CC1=CC=CC(NC=2NCCN=2)=C1Cl BFGSSXYIVHXPCN-UHFFFAOYSA-N 0.000 description 1
125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000012299 nitrogen atmosphere Substances 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
239000002245 particle Substances 0.000 description 1
BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical compound O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
125000003386 piperidinyl group Chemical group 0.000 description 1
229920000058 polyacrylate Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229920002689 polyvinyl acetate Polymers 0.000 description 1
239000011118 polyvinyl acetate Substances 0.000 description 1
229910000027 potassium carbonate Inorganic materials 0.000 description 1
RFAKLMBNSZNUNX-UHFFFAOYSA-N potassium;isothiocyanate Chemical compound [K+].[N-]=C=S RFAKLMBNSZNUNX-UHFFFAOYSA-N 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
125000004309 pyranyl group Chemical group O1C(C=CC=C1)* 0.000 description 1
125000003373 pyrazinyl group Chemical group 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
125000000714 pyrimidinyl group Chemical group 0.000 description 1
HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
239000003507 refrigerant Substances 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000000452 restraining effect Effects 0.000 description 1
239000004208 shellac Substances 0.000 description 1
235000013874 shellac Nutrition 0.000 description 1
ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
229940113147 shellac Drugs 0.000 description 1
RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
206010041232 sneezing Diseases 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
210000005070 sphincter Anatomy 0.000 description 1
SETMGIIITGNLAS-UHFFFAOYSA-N spizofurone Chemical compound O=C1C2=CC(C(=O)C)=CC=C2OC21CC2 SETMGIIITGNLAS-UHFFFAOYSA-N 0.000 description 1
229950001870 spizofurone Drugs 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
239000000021 stimulant Substances 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 description 1
125000003831 tetrazolyl group Chemical group 0.000 description 1
125000004525 thiadiazinyl group Chemical group S1NN=C(C=C1)* 0.000 description 1
125000000335 thiazolyl group Chemical group 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
125000001544 thienyl group Chemical group 0.000 description 1
BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 1
150000003585 thioureas Chemical class 0.000 description 1
239000004408 titanium dioxide Substances 0.000 description 1
235000010215 titanium dioxide Nutrition 0.000 description 1
XFYDIVBRZNQMJC-UHFFFAOYSA-N tizanidine Chemical compound ClC=1C=CC2=NSN=C2C=1NC1=NCCN1 XFYDIVBRZNQMJC-UHFFFAOYSA-N 0.000 description 1
229960000488 tizanidine Drugs 0.000 description 1
210000003437 trachea Anatomy 0.000 description 1
210000001635 urinary tract Anatomy 0.000 description 1
235000016788 valerian Nutrition 0.000 description 1
235000012141 vanillin Nutrition 0.000 description 1
MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
239000000080 wetting agent Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/44—Nitrogen atoms not forming part of a nitro radical
- C07D233/50—Nitrogen atoms not forming part of a nitro radical with carbocyclic radicals directly attached to said nitrogen atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Urology & Nephrology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

UA97115588A 1995-04-20 1996-04-13 ItarasPHARMACEUTICAL COMPOSITION BASED ON a1L-AGONSISTS FOR TREATING INCONTINENCE (VARIANTS) AND PHENYLAMINOIMIDASOLIN (VARIANTS) UA62913C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DE19514579A DE19514579A1 (de)	1995-04-20	1995-04-20	Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
PCT/EP1996/001568 WO1996032939A1 (de)	1995-04-20	1996-04-13	VERWENDUNG VON α1L-AGONISTEN ZUR BEHANDLUNG DER HARNINKONTINENZ

Publications (1)

Publication Number	Publication Date
UA62913C2 true UA62913C2 (en)	2004-01-15

Family

ID=7759982

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA97115588A UA62913C2 (en)	1995-04-20	1996-04-13	ItarasPHARMACEUTICAL COMPOSITION BASED ON a1L-AGONSISTS FOR TREATING INCONTINENCE (VARIANTS) AND PHENYLAMINOIMIDASOLIN (VARIANTS)

Country Status (31)

Country	Link
US (4)	US6268389B1 (xx)
EP (2)	EP1285653A1 (xx)
JP (2)	JP3379960B2 (xx)
KR (1)	KR19990007985A (xx)
CN (1)	CN1119148C (xx)
AR (1)	AR002043A1 (xx)
AU (1)	AU719710B2 (xx)
BG (1)	BG64116B1 (xx)
BR (1)	BR9608049A (xx)
CA (1)	CA2214338C (xx)
CZ (1)	CZ327197A3 (xx)
DE (2)	DE19514579A1 (xx)
EE (1)	EE04416B1 (xx)
ES (1)	ES2279521T3 (xx)
HR (1)	HRP960187A2 (xx)
HU (1)	HUP9801599A3 (xx)
IL (1)	IL117956A (xx)
MX (1)	MX9707570A (xx)
NO (1)	NO974821L (xx)
NZ (1)	NZ307509A (xx)
PE (1)	PE44297A1 (xx)
PL (1)	PL184881B1 (xx)
RU (2)	RU2230061C2 (xx)
SK (1)	SK138097A3 (xx)
TR (1)	TR199701212T1 (xx)
TW (1)	TW403739B (xx)
UA (1)	UA62913C2 (xx)
UY (1)	UY24206A1 (xx)
WO (1)	WO1996032939A1 (xx)
YU (1)	YU24496A (xx)
ZA (1)	ZA963131B (xx)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE19514579A1 (de) *	1995-04-20	1996-10-24	Boehringer Ingelheim Kg	Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
SG72827A1 (en) *	1997-06-23	2000-05-23	Hoffmann La Roche	Phenyl-and aminophenyl-alkylsulfonamide and urea derivatives
US6503935B1 (en)	1998-08-07	2003-01-07	Abbott Laboratories	Imidazoles and related compounds as α1A agonists
GB9906192D0 (en)	1999-03-18	1999-05-12	Medical Res Council	Photoreleasable compounds
US6323231B1 (en)	2000-02-17	2001-11-27	Abbott Laboratories	Use of α1A adrenoceptor agonists with α1B and α1D antagonism for the treatment of stress urinary incontinence
US6602897B2 (en)	2000-10-14	2003-08-05	Boehringer Ingelheim Pharma Kg	m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence
DE10150312A1 (de) *	2000-10-14	2002-07-04	Boehringer Ingelheim Pharma	Neue m-Amino-phenylimino-imidazolidin-Derivate zur Behandlung der Harninkontinenz
GB0030580D0 (en) *	2000-12-15	2001-01-31	Medicare Man Consultancy Ltd	Composition and method
US6660772B2 (en)	2001-02-01	2003-12-09	Boehringer Ingelheim Pharma Kg	Use of 2-amino-1-(4-hydroxy-2-methanesulfonamidophenyl)ethanol for treating urinary incontinence
DE10104369A1 (de) *	2001-02-01	2002-08-08	Boehringer Ingelheim Pharma	Verwendung von 2-Amino-(4-hydroxy-2-methansulfonamidophenyl)ethanol zur Behandlung der Harninkontinenz
US20020169193A1 (en) *	2001-02-10	2002-11-14	Pascale Pouzet	Alkylphenyliminoimidazolidine derivatives for treating urinary incontinence
DE10106214A1 (de) *	2001-02-10	2002-08-14	Boehringer Ingelheim Pharma	Neue Alkyl-phenylimino-imidazolidin-Derivate zur Behandlung der Harninkontinenz
GB0114008D0 (en) *	2001-06-08	2001-08-01	Perry Robert E	New therapautic use
US20040220240A1 (en) *	2001-11-28	2004-11-04	Pellegrini Cara A.	Method of increasing the extent of absorption of tizanidine
US6455557B1 (en) *	2001-11-28	2002-09-24	Elan Pharmaceuticals, Inc.	Method of reducing somnolence in patients treated with tizanidine
US6703409B2 (en)	2002-01-31	2004-03-09	Boehringer Ingelheim Pharma Gmbh & Co Kg	2′-Halo-3′,5′-dialkoxyphen-1′-yl-imino-2-imidazolidine and the use thereof as a drug
EP1333028A1 (en) *	2002-01-31	2003-08-06	Boehringer Ingelheim Pharma GmbH & Co.KG	2'-Halo-3',5'-dialkoxyphen-1'-yl-imino-2-imidazolidine derivatives and the use thereof for the treatment of urinary incontinence
CA2473803A1 (en) *	2002-02-01	2003-08-07	Robert Greenhouse	Substituted indoles as alpha-1 agonists
DE10352132A1 (de) *	2003-11-04	2005-06-09	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Pharmazeutische Zusammensetzung aus einem Beta-3-Adrenozeptor-Agonisten und einem Alpha Agonisten
RU2473545C2 (ru) *	2007-02-02	2013-01-27	Ф.Хоффманн-Ля Рош Аг	Новые 2-аминооксазолины в качестве лигандов taar1 для заболеваний цнс
KR101222412B1 (ko) *	2007-02-15	2013-01-15	에프. 호프만-라 로슈 아게	Ｔａａｒ1 리간드로서의 2-아미노옥사졸린
JP2010535172A (ja) *	2007-08-02	2010-11-18	エフ．ホフマン−ラロシュアーゲー	Ｃｎｓ障害の処置のためのベンズアミド誘導体の使用
US8426454B2 (en) *	2007-08-15	2013-04-23	Allergan, Inc.	Therapeutic compounds
CN101855213B (zh) *	2007-08-15	2014-09-10	阿勒根公司	治疗性化合物
JP4168086B1 (ja) *	2008-04-16	2008-10-22	国立大学法人福井大学	イミダゾリン誘導体
US8242153B2 (en) *	2008-07-24	2012-08-14	Hoffmann-La Roche Inc.	4,5-dihydro-oxazol-2YL derivatives
JP5547187B2 (ja) *	2008-07-24	2014-07-09	エフ．ホフマン−ラロシュアーゲー	４，５−ジヒドロ−オキサゾール−２−イル誘導体
GB2466622A (en) *	2008-12-23	2010-06-30	Trinity College Dublin	Alpha2-Adrenoceptor Ligands
US20100311798A1 (en) *	2009-06-05	2010-12-09	Decoret Guillaume	2-aminooxazolines as taar1 ligands
US8354441B2 (en) *	2009-11-11	2013-01-15	Hoffmann-La Roche Inc.	Oxazoline derivatives
US9452980B2 (en)	2009-12-22	2016-09-27	Hoffmann-La Roche Inc.	Substituted benzamides
WO2012008565A1 (ja) *	2010-07-16	2012-01-19	日本ケミファ株式会社	イミダゾリン誘導体
DK2624696T3 (en)	2010-10-06	2017-03-13	Glaxosmithkline Llc Corp Service Company	BENZIMIDAZOLD DERIVATIVES AS PI3-KINASE INHIBITORS
JPWO2015152196A1 (ja) *	2014-03-31	2017-04-13	東レ株式会社	イミダゾリン誘導体及びその医薬用途
SG11201807516UA (en)	2016-03-17	2018-09-27	Hoffmann La Roche	5-ethyl-4-methyl-pyrazole-3-carboxamide derivative having activity as agonist of taar

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2899426A (en) *		1959-08-11		Synthesis of l
DE71554C (de) *			B. BROCKHUES, in Firma BROCKHUES & ClE, in Köln a. Rh	Leicht transportable Nothlaschung für Schienenbrüche
US2744910A (en) *	1955-06-27	1956-05-08	Bristol Lab Inc	2-(ortho-benzylbenzyl)-imidazoline and acid addition salts
US2915431A (en) *	1956-07-17	1959-12-01	Lab Robert & Carriere Sa Des	2-(2'-isopropyl-4'-chloro-5'-methyl)-phenoxymethyl-2-imidazoline and its pharmaceutical uses
US3081222A (en) *	1960-03-11	1963-03-12	Us Rubber Co	Fungicides
US3202660A (en)	1961-10-09	1965-08-24	Boehringer Sohn Ingelheim	Process for the preparation of 3-arylamino-1, 3-diazacycloalkenes
AT285599B (de)	1968-06-21	1970-11-10	Boehringer Sohn Ingelheim	Verfahren zur Herstellung von neuen trisubstituierten 2-Arylaminoimidazolinen und ihren Salzen
BE754820R (fr) *	1969-08-13	1971-02-15	Schering Ag	Nouveaux derives de pyrimidine, leurs procedes de preparation et leurs
DE2316377C3 (de)	1973-04-02	1978-11-02	Lentia Gmbh, Chem. U. Pharm. Erzeugnisse - Industriebedarf, 8000 Muenchen	Verfahren zur Herstellung von 2-Phenyl-amino-2-imidazolin-Derivaten und von deren Salzen
FR2269341B1 (xx) *	1974-04-30	1978-07-28	Castaigne Sa
MTP837B (en) *	1977-11-07	1979-10-22	Hoffman La Roche And Co Aktien	Derivatives 2 finino-imidazolidire
DE2806811A1 (de) *	1978-02-17	1979-08-23	Boehringer Sohn Ingelheim	Neue substituierte 2-phenylimino- imidazolidine, deren saeureadditionssalze, diese enthaltene arzneimittel und verfahren zur herstellung derselben
DE2806775A1 (de) *	1978-02-17	1979-08-30	Boehringer Sohn Ingelheim	Neue substituierte 2-phenylimino- imidazolidine deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben
DE2811847A1 (de)	1978-03-17	1979-09-20	Lentia Gmbh	Neue arylaminoimidazolinderivate, deren herstellung und verwendung als arzneimittel
US4226713A (en)	1978-04-24	1980-10-07	Goldberg Jack M	Diagnostic agents
US4262005A (en) *	1978-05-31	1981-04-14	The Boots Company Limited	Compounds, compositions and methods for controlling pests
US4323570A (en) *	1978-11-15	1982-04-06	Beiersdorf Aktiengesellschaft	Substituted aminopyrimidines
DE2854659A1 (de) *	1978-12-18	1980-07-10	Boehringer Sohn Ingelheim	Neue 3,4-disubstituierte 2-phenylimino-imidazolidine, deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zu deren herstellung
US4226773A (en) *	1979-05-07	1980-10-07	Abbott Laboratories	Pyrazolyl amino imidazolines as diuretic agents
DE2949287A1 (de)	1979-12-07	1981-06-11	C.H. Boehringer Sohn, 6507 Ingelheim	Neue substituierte 2-phenylamino-imidazoline-(2), deren saeureadditionssalze, diese enthaltende arzneimittel und verfahren zur herstellung derselben
US4287201A (en) *	1980-03-03	1981-09-01	Merck & Co., Inc.	Anovulatory method and chicken feed compositions
DE3168754D1 (en) *	1980-07-09	1985-03-21	Beecham Group Plc	Clonidine derivatives useful in the treatment of diarrhoea
EP0070084A3 (en) *	1981-04-24	1983-02-16	Beecham Group Plc	Imidazoline derivatives
DE3133886A1 (de)	1981-08-27	1983-03-17	Bayer Ag, 5090 Leverkusen	2-arylazo-2-imidazoline, acylderivate derselben, verfahren zu ihrer herstellung und die verwendung zur bekaempfung von ekto- und/oder endoparasiten
CA1201066A (en) *	1981-11-20	1986-02-25	Alcon Laboratories, Inc.	N-¬3,5-dichloro-4-(2-imidazolidinylideneamino)- phenyl\|-acetamide solutions for lowering intraocular pressure
US4644007A (en)	1981-11-20	1987-02-17	Alcon Laboratories, Inc.	3-chloro-4-(4,5-dihydro-1H-imidazo-2-yl)-amino-5-alkylbenzoic acids, esters, salts, compositions and methods
US4517199A (en) *	1981-11-20	1985-05-14	Alcon Laboratories, Inc.	Method for lowering intraocular pressure using phenylimino-imidazoles
US4461904A (en) *	1981-11-20	1984-07-24	Alcon Laboratories, Inc.	2-(Trisubstituted phenylimino)-imidazolines
FR2521140A1 (fr)	1982-02-05	1983-08-12	Synthelabo	Derives d'imidazolidine, leur preparation et leur application en therapeutique
GB8304593D0 (en)	1983-02-18	1983-03-23	Beecham Group Plc	Amidines
GB8333835D0 (en) *	1983-12-20	1984-02-01	Beecham Group Plc	Compounds
EP0236636A3 (en) *	1986-02-07	1988-12-07	Alcon Laboratories, Inc.	Use of clonidine derivatives for the preparation of ocular hemostatic agents
US4587257A (en) *	1984-12-14	1986-05-06	Alcon Laboratories, Inc.	Control of ocular bleeding using clonidine derivatives
US4861904A (en) *	1986-04-17	1989-08-29	Agency Of Industrial Science And Technology	Schiff base metal complex compounds, and organometallic ultrathin film composed thereof and oxygen separation films composed thereof
GB8610909D0 (en) *	1986-05-03	1986-06-11	Beecham Group Plc	Compounds
US4861189A (en)	1987-02-26	1989-08-29	Kajima Corporation	System for paving inclined and/or curved surfaces
US4801617A (en)	1987-04-06	1989-01-31	Leclerc Gerard	Iminoimidazolidines useful in lowering intraocular pressure
DE3712385A1 (de) *	1987-04-11	1988-10-27	Boehringer Ingelheim Kg	2-(phenylimino)imidazolidine
CA2024428A1 (en) *	1989-09-06	1991-03-07	Masayuki Ishikawa	Agent for treating urinary obstruction
US5130441A (en) *	1990-02-06	1992-07-14	Allergan, Inc.	Method for producing amino-2-imidazoline derivatives
US5237072A (en) *	1990-02-06	1993-08-17	Allergan, Inc.	Method for producing amino-2-imidazoline derivatives
IE911994A1 (en) *	1990-07-03	1992-01-15	Akzo Nv	5-isothiazolamine derivatives
WO1994008040A1 (en) *	1992-09-25	1994-04-14	Synaptic Pharmaceutical Corporation	Dna encoding human alpha 1 adrenergic receptors and uses thereof
US5237032A (en)	1992-09-30	1993-08-17	Istituto Guido Donegani S.P.A.	Microwave processing of carbonate monomers
EP0599697A1 (fr) *	1992-11-24	1994-06-01	Synthelabo	Dérivés de pyrrole, leur préparation et leur application en thérapeutique
US5447916A (en) *	1993-07-30	1995-09-05	Chiron Corporation	Peptoid alpha-1 adrenergic receptor ligands
JP3805360B2 (ja)	1994-01-24	2006-08-02	アラーガン、インコーポレイテッド	α▲下２Ａ▼アドレナリン受容体作動剤としての芳香族２−アミノ−イミダゾール誘導体
FR2719844B1 (fr) *	1994-05-10	1996-06-07	Synthelabo	Dérivés de 5,6-dihydro-4h-thiéno[3,4-c]pyrrole, leur préparation et leur application en thérapeutique.
DE19514579A1 (de) *	1995-04-20	1996-10-24	Boehringer Ingelheim Kg	Verwendung von alpha¶1¶¶L¶-Agonisten zur Behandlung der Harninkontinenz
US5866579A (en) *	1997-04-11	1999-02-02	Synaptic Pharmaceutical Corporation	Imidazole and imidazoline derivatives and uses thereof
US6602897B2 (en) *	2000-10-14	2003-08-05	Boehringer Ingelheim Pharma Kg	m-Amino-phenylimino-imidazolidine derivatives for treating urinary incontinence

1995
- 1995-04-20 DE DE19514579A patent/DE19514579A1/de not_active Withdrawn
1996
- 1996-04-13 KR KR1019970707509A patent/KR19990007985A/ko active IP Right Grant
- 1996-04-13 RU RU97119064/15A patent/RU2230061C2/ru not_active IP Right Cessation
- 1996-04-13 NZ NZ307509A patent/NZ307509A/xx unknown
- 1996-04-13 CZ CZ973271A patent/CZ327197A3/cs unknown
- 1996-04-13 JP JP53145596A patent/JP3379960B2/ja not_active Expired - Fee Related
- 1996-04-13 PL PL96324041A patent/PL184881B1/pl not_active IP Right Cessation
- 1996-04-13 ES ES96914912T patent/ES2279521T3/es not_active Expired - Lifetime
- 1996-04-13 EP EP02025309A patent/EP1285653A1/de not_active Withdrawn
- 1996-04-13 BR BR9608049A patent/BR9608049A/pt not_active Application Discontinuation
- 1996-04-13 UA UA97115588A patent/UA62913C2/uk unknown
- 1996-04-13 CN CN96193093A patent/CN1119148C/zh not_active Expired - Fee Related
- 1996-04-13 TR TR97/01212T patent/TR199701212T1/xx unknown
- 1996-04-13 DE DE59611411T patent/DE59611411D1/de not_active Expired - Lifetime
- 1996-04-13 AU AU56878/96A patent/AU719710B2/en not_active Ceased
- 1996-04-13 EE EE9700267A patent/EE04416B1/xx not_active IP Right Cessation
- 1996-04-13 SK SK1380-97A patent/SK138097A3/sk unknown
- 1996-04-13 HU HU9801599A patent/HUP9801599A3/hu unknown
- 1996-04-13 CA CA2214338A patent/CA2214338C/en not_active Expired - Fee Related
- 1996-04-13 EP EP96914912A patent/EP0821585B1/de not_active Expired - Lifetime
- 1996-04-13 MX MX9707570A patent/MX9707570A/es not_active IP Right Cessation
- 1996-04-13 WO PCT/EP1996/001568 patent/WO1996032939A1/de active IP Right Grant
- 1996-04-14 UY UY24206A patent/UY24206A1/es not_active IP Right Cessation
- 1996-04-18 TW TW085104648A patent/TW403739B/zh not_active IP Right Cessation
- 1996-04-18 IL IL11795696A patent/IL117956A/en not_active IP Right Cessation
- 1996-04-19 YU YU24496A patent/YU24496A/sh unknown
- 1996-04-19 PE PE1996000273A patent/PE44297A1/es not_active Application Discontinuation
- 1996-04-19 ZA ZA963131A patent/ZA963131B/xx unknown
- 1996-04-19 HR HR19514579.8A patent/HRP960187A2/hr not_active Application Discontinuation
- 1996-04-22 AR ARP960102266A patent/AR002043A1/es unknown
1997
- 1997-10-15 BG BG101966A patent/BG64116B1/bg unknown
- 1997-10-17 NO NO974821A patent/NO974821L/no not_active Application Discontinuation
1999
- 1999-01-11 US US09/227,944 patent/US6268389B1/en not_active Expired - Lifetime
2000
- 2000-03-28 US US09/536,728 patent/US20020040150A1/en not_active Abandoned
2002
- 2002-08-14 JP JP2002236562A patent/JP4141763B2/ja not_active Expired - Fee Related
- 2002-11-15 US US10/295,460 patent/US6858594B2/en not_active Expired - Lifetime
2003
- 2003-02-07 RU RU2003104267/15A patent/RU2003104267A/ru not_active Application Discontinuation
2004
- 2004-04-19 US US10/827,408 patent/US7019021B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
AR002043A1 (es)	1998-01-07
NO974821D0 (no)	1997-10-17
EE04416B1 (et)	2005-02-15
JPH11503738A (ja)	1999-03-30
EE9700267A (et)	1998-06-15
PL184881B1 (pl)	2003-01-31
EP1285653A1 (de)	2003-02-26
DE19514579A1 (de)	1996-10-24
PE44297A1 (es)	1997-10-27
US7019021B2 (en)	2006-03-28
EP0821585A1 (de)	1998-02-04
ZA963131B (en)	1996-10-21
DE59611411D1 (de)	2007-02-22
CA2214338A1 (en)	1996-10-24
IL117956A0 (en)	1996-08-04
TW403739B (en)	2000-09-01
RU2003104267A (ru)	2004-08-27
CN1119148C (zh)	2003-08-27
BG101966A (en)	1998-09-30
US20030114425A1 (en)	2003-06-19
HRP960187A2 (en)	1997-12-31
UY24206A1 (es)	2000-08-21
RU2230061C2 (ru)	2004-06-10
AU5687896A (en)	1996-11-07
HUP9801599A2 (hu)	1999-01-28
WO1996032939A1 (de)	1996-10-24
TR199701212T1 (xx)	1998-03-21
US20040198796A1 (en)	2004-10-07
CN1180311A (zh)	1998-04-29
ES2279521T3 (es)	2007-08-16
CA2214338C (en)	2010-10-19
US6858594B2 (en)	2005-02-22
YU24496A (sh)	1998-12-23
US6268389B1 (en)	2001-07-31
JP3379960B2 (ja)	2003-02-24
NZ307509A (en)	2000-06-23
NO974821L (no)	1997-10-17
PL324041A1 (en)	1998-05-11
AU719710B2 (en)	2000-05-18
KR19990007985A (ko)	1999-01-25
SK138097A3 (en)	1998-02-04
JP4141763B2 (ja)	2008-08-27
BR9608049A (pt)	1999-01-26
US20020040150A1 (en)	2002-04-04
BG64116B1 (bg)	2004-01-30
JP2003064058A (ja)	2003-03-05
MX9707570A (es)	1997-12-31
HUP9801599A3 (en)	1999-04-28
IL117956A (en)	2001-11-25
CZ327197A3 (cs)	1998-05-13
EP0821585B1 (de)	2007-01-10

Publication	Publication Date	Title
UA62913C2 (en)	2004-01-15	ItarasPHARMACEUTICAL COMPOSITION BASED ON a1L-AGONSISTS FOR TREATING INCONTINENCE (VARIANTS) AND PHENYLAMINOIMIDASOLIN (VARIANTS)
KR20010022877A (ko)	2001-03-26	신경계 장애를 치료하기 위한 헤테로사이클릭 비닐에테르
US3803324A (en)	1974-04-09	Amino-guanidine derivatives useful for regulating blood pressure
US6492407B2 (en)	2002-12-10	Pharmaceutical compositions containing triazolones and methods of treating neurodegenerative disease using triazolones
EP0500337A1 (en)	1992-08-26	Composition containing aryl-substituted rhodanine derivatives for the treatment of type I diabetes
US3927011A (en)	1975-12-16	2-Aminoalkyl-1-(pyridylcarbonylphenyl)imidazole compounds
US4421753A (en)	1983-12-20	1-(5-Amino-4H-1,2,4-triazol-3-yl)-4-substituted-piperazines
US5025015A (en)	1991-06-18	Thioformamidines, and use as medicaments
GB2096987A (en)	1982-10-27	Substituted imidazole and imidazole derivatives and their preparation and use
US3632602A (en)	1972-01-04	2-(2-arylhydrazino)-2-imidazolines
EP0251141A1 (en)	1988-01-07	Piperazine compounds, process for preparing them, pharmaceutical composition and use
EP0050407A1 (en)	1982-04-28	3,5-Disubstituted-1,2,4-triazole compounds, processes for their preparation and pharmaceutical compositions containing them
MXPA04007250A (es)	2004-10-29	2??-halo-3??, 5??-dialcoxi-fen-1??-il-imino-2-imidazolidinas y su uso como un farmaco.
EP1341777B1 (en)	2007-09-26	1-(2-m-methanesulfonamidophenylethyl)-4-(m-trifluoromethylphenyl)piperazine and pharmaceutically acceptable salts and solvates thereof and their use in the treatement of incontinence
EP0457331B1 (en)	1996-11-20	Piperidine derivatives and antiulcer composition containing the same
CA1322525C (en)	1993-09-28	Use of 1-benzyl-aminoalkyl-pyrrolidinones as antidepressants
US3549756A (en)	1970-12-22	Antitrichomonal compositions containing 1-substituted - 2 - morpholinyl or thiamorpholinyl-5-nitroimidazoles
EP1532978A1 (en)	2005-05-25	Remedy for urinary frequency and urinary incontinence